CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?

CRISPR Therapeutics (CRSP) stock has risen 11.1% in the past month, outperforming the S&P 500; however, consensus estimates have shifted downward by -20.48% over the same period. The stock holds a Zacks Rank #3 (Hold), suggesting expectations of an in-line return in the coming months, and has a weak VGM score of D, driven by a grade of F on the value side. In comparison, Exact Sciences (EXAS), a peer in the same industry, gained 3.6% over the past month, reporting a 10.9% year-over-year revenue increase and improved EPS.

Analysis

CRISPR Therapeutics AG (CRSP) has demonstrated notable share price appreciation, rising 11.1% over the past month and outperforming the S&P 500, despite a significant downward revision in consensus estimates by -20.48% during the same period. The company currently holds a Zacks Rank #3 (Hold), indicating expectations for an in-line return relative to the market in the near term. Its overall VGM Score is D, reflecting a C for Growth, a B for Momentum, but a concerning F for Value, placing it in the bottom quintile for this investment style; this suggests that while recent market momentum has been positive, underlying valuation metrics are weak. In contrast, industry peer Exact Sciences (EXAS) gained 3.6% over the past month and recently reported a 10.9% year-over-year revenue increase to $706.78 million for the quarter ended March 2025, with an improved EPS of -$0.21 compared to -$0.50 a year ago. Exact Sciences, also holding a Zacks Rank #3 (Hold), is expected to further improve its EPS to a loss of $0.08 per share in the current quarter, a +11.1% year-over-year change, and its consensus estimates have remained stable over the last 30 days, supported by a stronger VGM Score of B.

Key Decisions for Investors

• Investors in CRISPR Therapeutics (CRSP) should exercise caution due to the divergence between its recent 11.1% share price increase and the substantial -20.48% downward revision in consensus analyst estimates, alongside a poor 'F' grade for Value.
• It is advisable to closely monitor CRSP's next earnings release and any forward-looking statements for justification of its recent stock performance, particularly given the 'Hold' rating and the significant negative shift in earnings estimates.
• Consider the relative profile of Exact Sciences (EXAS), which, despite a more modest recent stock gain of 3.6%, exhibits positive revenue growth, improving EPS, stable analyst estimates, and a superior VGM score of B, potentially indicating a more fundamentally supported position within the sector.